WO2014104605A1 - 신규한 암 병변 표지용 조성물 - Google Patents
신규한 암 병변 표지용 조성물 Download PDFInfo
- Publication number
- WO2014104605A1 WO2014104605A1 PCT/KR2013/011177 KR2013011177W WO2014104605A1 WO 2014104605 A1 WO2014104605 A1 WO 2014104605A1 KR 2013011177 W KR2013011177 W KR 2013011177W WO 2014104605 A1 WO2014104605 A1 WO 2014104605A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- icg
- maa
- complex
- composition
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
- G01N2333/765—Serum albumin, e.g. HSA
Definitions
- the present invention relates to a novel composition for labeling cancer lesions, and more particularly, the present invention includes a complex in which a dye for biological tissue staining, a radioisotope, or a combination thereof is bound to a macroaggregated albumin (MAA).
- a composition for labeling cancer lesions a method for providing information on the location of cancer lesions using the composition for labeling cancer lesions, a kit for labeling cancer lesions comprising the composition for labeling cancer lesions and a composition for labeling cancer lesions It relates to a complex in which the dye for biological tissue stain is bound to the corresponding albumin.
- the location of the patient's micro lesions is confirmed by ultrasound, mammography, or magnetic resonance imaging before the operation, the location of the identified lesion is marked, and the tissue of the marked area is removed.
- a method of drawing on the surface of the skin, using a wire, or injecting a black pigment such as charcoal is used.
- the method of drawing with a pen on the skin to indicate the location of the lesion is that the shape of the breast changes a lot in the operating room unlike when diagnosed due to the characteristics of very flexible breast tissue.
- the display is insufficient only by marking on the surface of the skin, which can be easily used, but has a disadvantage of low accuracy.
- the use of wire to pierce breast lesions requires the wire to be inserted vertically into the skin surface but must be inserted obliquely as it may affect the ultrasound probe, and the location of the wire is the movement of the breast. Due to the fact that it can move according to the lower accuracy than expected, the inserted wire interferes with the surgery, there is a disadvantage that the procedure to remove the insertion portion of the wire must be performed additionally.
- the method of injecting a pigment such as charcoal has the advantage that the injected pigment binds to the lesion and accurately marks the location of the lesion, whereas in the case of a deep breast, black pigment cannot be identified from the outside.
- the surgical site may be contaminated by pigments. This disadvantage is also equally problematic in surgical operations to remove cancerous tissues other than breast cancer.
- the marker including the corresponding albumin combined with the pigment for biotissue staining can be effectively adsorbed to the lesion of the cancer to accurately label the location of the lesion, the pigment in real time After confirming that the scope of the lesion to be removed can be accurately identified, and completed the present invention.
- An object of the present invention is to provide a composition for labeling cancer lesions comprising a complex in which a dye for biological tissue staining, a radioisotope, or a combination thereof is bound to a macroaggregated albumin (MAA).
- MAA macroaggregated albumin
- Another object of the present invention to provide a method for providing information on the location of cancer lesions using the composition for labeling cancer lesions.
- Still another object of the present invention is to provide a kit for labeling cancer lesions comprising the composition for labeling cancer lesions.
- Still another object of the present invention is to provide a complex in which a dye for biological tissue dye is combined with corresponding albumin included in the cancer lesion labeling composition.
- the present invention provides a composition for labeling cancer lesions comprising a complex in which a dye for biological tissue staining, a radioisotope or a combination thereof is bound to a macroaggregated albumin (MAA).
- the cancer labeled by the composition is not particularly limited as long as it contains a tissue that can be fixed by penetrating the MAA, but is preferably a solid cancer that can be fixed by penetrating the MAA in the tissue, for example, the prostate Cancer, breast cancer, uterine cancer, skin cancer, cervical cancer, lung cancer, brain tumor, gastrointestinal tumor, liver cancer, soft tissue sarcoma, lymphoma and the like.
- the term "macroaggregated albumin (MAA)” refers to protein particles having a diameter of 10 to 50 ⁇ m prepared by heating and coagulating human serum albumin, compared with human serum albumin having a diameter of less than 10 nm. The structure and physical properties are different. When the MAA is injected intravenously, it shows a characteristic that can be retained in the lung capillary tube of about 8 ⁇ m and cause microembolization. Using this characteristic, the MAA labeled with radioisotope is a lung sinogram (obstruction).
- Pulmonary blood flow abnormalities such as anterior, pulmonary thrombosis, ocular disease, pneumonia, lung cancer, diagnosis of right / left shant or pulmonary venous hypertension, venous scan (central venous hemodiagnosis at that site), or venous scan (peripheral artery blood flow such as paja disease) Diagnosis).
- the MAA of the present invention is used as a medium for injecting cancer markers into the cancer lesion tissue and binding the marker to the cancer lesion tissue.
- the MAA of the present invention can be synthesized using recombinant HSA, and can also be synthesized using non-self-derived HSA. It is also possible to purchase and use a commercially available one.
- the MAA of the present invention is used as a mediator for binding a marker to cancer lesion tissue by injecting it into a cancer lesion tissue, and the mediator serves to prevent the marker from spreading into the cancer lesion tissue by adsorbing the marker substance. To perform.
- the term "pigment for dyeing biological tissues” refers to a substance which allows a labeled position to be identified by binding to biological tissues and visually or using a detection tool.
- the dye for biological tissue dyeing may be a labeling substance that can be used for labeling cancer-generating sites by binding to cancer tissues. Fluorescent dyes that can be detected using equipment such as fluorescent cameras can be used alone or in combination, but are not particularly limited thereto.
- the "pigmentally identifiable pigment” means a kind of pigment that allows the labeling substance bound to the biological tissue to show the color of the visible light region so that the labeled portion can be visually identified.
- the visually identifiable pigment is injected into the site where the cancer has occurred to remove the cancer by a surgical method, so that the cancer lesion to be resected can be clearly identified, thereby improving the success rate of cancer surgery. Can be performed.
- the visually identifiable labeling substance is preferably neutral, nile blue, bismarck brown, lithium carmine, trypan blue, janus green, methyl violet, o-lamin, marragite green, safranin, eosin, congo red, erythrosin , Nigrosine, alkyan blue hematoxylin, aniline blue, light green and the like can be used alone or in combination, but as long as it can achieve the purpose of identifying cancer lesion tissue is not particularly limited.
- fluorescent dye refers to an organic compound that absorbs light of a certain wavelength and forms an excited state, whereby a light penetration distance is maximized and generates fluorescence capable of minimizing error signals caused by moisture.
- it may be a near-infrared fluorescent dye, which is an organic compound that generates fluorescence of a near infrared wavelength of preferably 700 nm to 3000 nm, preferably 750 nm to 900 nm. Fluorescence of near-infrared wavelengths generated from the near-infrared fluorescent dye may be photographed or monitored in real time using equipment such as a fluorescent camera and a fluorescence sensing probe (PCT / KR2011 / 009271).
- the fluorescence of the near-infrared wavelength of the present invention is relatively less absorbed in vivo than other wavelength bands, so that near-infrared radiation generated in a deep region of the living body can be detected outside of the body.
- the near-infrared region fluorescent dye is injected into the site where the cancer is generated to remove the cancer by a surgical method, so that the lesion site of the cancer can be accurately identified before the incision, thereby improving the success rate of the cancer surgery. It can play a role.
- the location of the lesion can be detected in vitro before the incision is made to confirm the direct lesion, thereby enabling rapid and accurate cancer surgery to be performed.
- the near-infrared fluorescent dye may preferably be indocyanine green and the like, and may be included in the scope of the present invention as long as it is a near-infrared fluorescent dye usable to the human body.
- the complex with the near-infrared fluorescent dye bound to the MAA exhibits the superior stability and accuracy of the detected fluorescence signal compared to the complex with the near-infrared fluorescent dye combined with another substance known to accumulate in the tumor, and thus, microscopic lesions may be found.
- the rate can be high, and the accuracy of lesion resection can be improved.
- indocyanine green refers to a dye for fluorescence imaging in the near-infrared region widely used in the biological or medical field, and disintegrates or disappears after an hour after being injected into the human body. Fluorescent dyes that can be used in the human body are advantageous for clinical application. Indeed, cases of indocyanine green application to humans have been reported in several papers, and have been reported to be clinically safe for use in 18 breast cancer patients, for example (T. Kitai, et al., Breast Cancer, 12: 211-215, 2005).
- the adsorption coupling of the near-infrared fluorescent dye may be achieved through the step of mixing the near-infrared fluorescent dye with the MAA of the present invention.
- a suitable mixing ratio for preparing a complex having a high near-infrared fluorescence signal in the preparation of the ICG-coupled complex (ICG-MAA) to the MAA is 3.9 for a MAA of 0.23 mg / ml. It was confirmed that the ICG of ⁇ M, the ICA of 6.5 ⁇ M for 2.3mg / ml MAA and the ICG of 6.5 ⁇ M for 11.5mg / ml MAA (Table 1 and Figure 4), in vivo when injected in vivo As the concentration changes due to diffusion, it is not possible to determine the exact concentration at the time of injection.
- the composite produced this way was found that in vitro, and the results confirmed whether representing the stability in the in vivo conditions, in vitro, and indicates the strength and stability of the near infrared fluorescent signal of relatively high levels of both the in vivo conditions (Fig. 5 And FIG. 6).
- the term "radioisotope” refers to an element having the same atomic number but different atomic weights and capable of emitting radiation, and generally uses a property of emitting radioactive attenuation by emitting gamma rays or other subatomic particles, thereby preventing disease. It is also used as an important marker for diagnosis.
- the radioisotope is injected into a deep-tissue tissue where the fluorescence generated by the near-infrared fluorescent dye is not detected, and the cancer is removed by a surgical method. By accurately identifying the lesion site, it can play a role in improving the success rate of cancer surgery.
- the radioisotope is not particularly limited as long as it exhibits a property capable of labeling MAA that can bind to cancerous lesions, but preferably H-3, C-14, P-32, S-35, and Cl-36. , Cr-51, Co-57, Co-58, Cu-64, Fe-59, Y-90, I-124, I-125, Re-186, I-131, Tc-99m, Mo-99, P -32, CR-51, Ca-45, Ca-68 and the like, more preferably medically used I-124, I-125, I-131, Cu-64, Tc-99m, Mo- 99, CR-51, Ca-45, Ca-68 and the like, and most preferably Tc-99m can be used.
- the cancer is not particularly limited, but is not particularly limited as long as it exhibits a characteristic that can be removed by surgical resection, but is not limited to prostate cancer, breast cancer, uterine cancer, skin cancer, cervical cancer, lung cancer, brain tumor, gastrointestinal tumor, liver cancer, soft tissue sarcoma, It can be most solid cancers, including lymphoma.
- a radioisotope when the radioisotope [Tc-99m] TcO 4 ⁇ is reacted with the MAA, a radioisotope is conjugated to the MAA in a yield of 99% or more, and these complexes are prepared.
- the radioisotope is reacted with the radioisotope [Tc-99m] TcO 4 - and the near - infrared fluorescent dye ICG sequentially in the MAA.
- a near-infrared fluorescent dye-combined complex [Tc-99m] Tc-ICG-MAA) can be prepared (FIG. 10), and the prepared complex can be confirmed injected even after 20 hours in vivo. (FIG. 11).
- fibrin can be used to enhance the physical properties of the complex.
- the complex of the present invention is injected into the lesion site in vivo to play a role of clearly identifying the lesion site at the time of surgery by displaying the lesion, such complex in order to smoothly carry out the purpose as the above-described markers Proliferation at the site of injected lesions should be prevented as much as possible. Fibrin can be used as one means to achieve this goal (FIG. 1).
- FIG. 1 is a schematic diagram showing that when fibrin is added to a complex including MAA and ICG, tissue retention in vivo of the complex is enhanced by the added fibrin.
- the fibrin may serve to connect the complexes injected in vivo to each other, thereby preventing the complexes injected into the living body from spreading as much as possible.
- the complex of the present invention may further comprise fibrin.
- ICG-MAA-fibrin complex prepared with blood coagulation fibrin (fibrin) was prepared.
- ICG-MAA ICG-coupled complexes
- a gelatin sponge may be used as another means for achieving the object of preventing the complex from being diffused in vivo.
- the complex may be formed to form a structure collected inside the gelatin in an aggregated form. The diffusion of the complex at the site injected by gelatin can be suppressed as much as possible.
- the gelatin since the gelatin has a disadvantage in that it is easily dissolved in the environment in vivo and the structure may collapse, it may be overcome by using a gelatin sponge instead of gelatin to solve this disadvantage.
- a gelatin sponge is a structure in which an isopeptide bond is formed between a side chain amine group of lysine and a side chain carboxyl group of glutamate or aspartate by heating the gelatin solution at a high temperature.
- the gelatin sponge exhibits the same biocompatibility as gelatin but relatively low solubility in water, and thus does not readily dissolve in vivo.
- the gelatin sponge is used to collect the complex of the present invention in an aggregated form. Forming and injecting the structure into the living body, the gelatin sponge does not dissolve in vivo, so that the injected structure does not collapse, it is possible to more effectively suppress the diffusion of the complex at the injected site.
- the gelatin solution is heated at 160 ° C. for 3 hours to prepare a gelatin sponge including a cross structure, and the gelatin and gelatin sponges are immersed in distilled water and left for 24 hours. While completely dissolved in distilled water, it was confirmed that the gelatin sponge did not dissolve in water and showed high stability (FIG. 12).
- the gelatin sponge described above When using the gelatin sponge described above, it may be configured to include near-infrared fluorescent dyes and radioisotopes simultaneously. That is, in the gelatin sponge, a complex in which the ICA is combined with the near-infrared fluorescent dye (MAG) in the MAA or [Tc-99m] Tc in which the radioisotope is the radioisotope in the MAA and the complex in which the ICG is combined with the near infrared fluorescent dye ([Tc] -99m] Tc-ICGMAA) may also be constructed.
- MAG near-infrared fluorescent dye
- Tc-99m] Tc-ICGMAA the complex in which the ICG is combined with the near infrared fluorescent dye
- the gelatin sponge may be manufactured to include a complex of a combination of ICG, which is a near-infrared fluorescent dye (MAG), and a radioisotope in the gelatin sponge, such that the complex and the radioisotope may be separately included.
- ICG which is a near-infrared fluorescent dye (MAG)
- MAG near-infrared fluorescent dye
- the gelatin sponge may further comprise means for more effectively immobilizing the radioisotope in the gelatin sponge.
- the immobilization means a gold foil coil in which radioisotopes are combined may be used, but the immobilization means is not particularly limited as long as the purpose of immobilizing the radioisotope can be achieved (FIG. 2).
- the present invention comprises the steps of (a) administering the composition for labeling cancer lesions to lesions of cancer developed in a subject; And (b) identifying a location from which the signal is selected from the group consisting of color, near infrared fluorescence, radiation and combinations thereof, wherein the location of the cancer lesion is provided. do.
- the term "individual” means a living organism in which cancer may develop and represent a lesion, and to which the complex or composition for cancer lesion labeling of the present invention may be administered.
- composition for labeling cancer lesions provided by the present invention When the composition for labeling cancer lesions provided by the present invention is administered to a cancerous lesion tissue in vivo, it may bind to the administered cancerous lesion and label the location of the lesion through color, near-infrared fluorescence, radioactivity, or a combination thereof.
- detecting the marker, the position, size, and the like of the cancer lesion can be detected in real time during surgery, thereby improving accuracy in removing the surgical cancer lesion and preventing excessive loss of normal tissue.
- the complex contained in the composition of the present invention can remain for a long time in cancer lesions in vivo, compared to the complex in which the dye for biological tissue staining in combination with other substances, so that not only during surgical resection of the cancer lesion, but also surgical The accuracy of cancer lesion resection by the procedure can be easily confirmed.
- the complex of the present invention is injected into the lesion site, and after several hours, the lesion site can be stably and accurately confirmed during surgery.
- FIG. 1 is a schematic diagram showing that when fibrin is added to a complex including MAA and ICG, tissue retention in vivo of the complex is enhanced by the added fibrin.
- Figure 2 is a schematic diagram showing the structure and injection method of the solid-type marker prepared by adding the radioisotope-bound gold foil coil and gelatin in a complex containing MAA and ICG.
- FIG. 3 is a gamma image photograph showing whether [Tc-99m] Tc-MAA changes over time in nude mice injected with [Tc-99m] Tc-MAA.
- Figure 4 is a graph showing the change of the near infrared fluorescence signal intensity of the ICG-MAA complex with the change of the concentration of ICG and MAA.
- Figure 6 is a photograph showing the change in intensity of near-infrared fluorescence signal over time of ICG-HSA, ICG-MAA, ICG-MAA-fibrin and ICGglycol chitosan complex injected into nude mice.
- Figure 7 is a photograph showing the form of each complex observed in chicken breast or pork belly injected with the ICG-MAA-fibrin complex or ICG-MAA complex.
- Figure 9 is a fluorescence picture showing the diffusion level over time of the ICG-MAA-fibrin complex and ICG-MAA complex injected in nude mice.
- FIG. 10 is a graph showing the labeling rate of the complex conjugated with Tc-99m in MAA.
- Figure 13 is a photograph showing the change in intensity of the near-infrared fluorescence signal over time of the radioactive isotope-bound gold foil coil, ICG, MAA and gelatin sponge and control group ICG-Spongostan.
- the complex was subjected to instant thin layer chromatography (ITLC) and developed using acetone as a solvent. As a result, more than 99% of thiol MAA is bound to the radioisotope. It was confirmed that the complex was formed.
- ICG indocyanine green
- MAA conjugates were expected to be used as markers that stably function in vivo, thus preparing the complexes and their usefulness as in vivo markers. Confirmed.
- ICG-MAA inocyanine green conjugated complex
- each ICG-MAA complex was prepared by reacting 1.3-1032 ⁇ M of ICG and 0-11.5 mg / ml of MAA in various ratios. Signal intensity of near-infrared fluorescence appearing in each of the prepared ICG-MAA complex was measured (Table 1 and FIG. 4).
- Figure 4 is a graph showing the change of the near infrared fluorescence signal intensity of the ICG-MAA complex with the change of the concentration of ICG and MAA.
- the ICG of 25.8 ⁇ M showed the highest value of near-infrared fluorescence signal intensity when the MAA was not treated, and the 3.9 ⁇ M ICG when the MAA was treated with 0.23 mg / ml.
- the highest value of near-infrared fluorescence signal intensity was shown, and when 2.3 mg / ml of MAA was treated, 6.5 ⁇ M of ICG showed the highest value of near-infrared fluorescence signal, and when treated with 11.5 mg / ml of MAA.
- the ICG of 6.5 ⁇ M also showed the highest NIR signal intensity.
- each complex (ICG-HSA, ICG-MAA and ICG-glycol chitosan) was prepared by adding 65 ⁇ M ICG to human serum albumin (HSA), glycol chitosan or MAA and reacting.
- HSA human serum albumin
- MAA glycol chitosan
- the ICG-MAA- to which blood coagulation (fibrin) is bound. fibrin complexes were prepared.
- the mixing ratio of fibrinogen, aprotinin, thrombin and CaCl 2 was set to 25 mg / ml, 500 KIU / ml, 250 IU / ml and 4 mg / ml, respectively.
- composition for tissue labeling is advantageous for use at the operating room when the injection site is labeled by injection into biological tissue and the injection site is longer, and thus the near-infrared fluorescence stability of the four complexes prepared in It was confirmed in vitro or in vivo .
- Example 3-3-2 in vivo Check stability
- Example 3-3 It was confirmed from the results of Example 3-3 that the ICG-MAA-fibrin complex and ICG-MAA complex including ICG-MAA exhibited very advantageous properties as cancer lesion markers. Compared.
- Figure 8 is a fluorescence picture showing the diffusion level over time of the ICG-MAA-fibrin complex and ICG-MAA complex injected into the muscle tissue.
- the ICG-MAA-fibrin complex is agglomerated after injection, causing the ICG-MAA to be trapped in the fibrin, but the size of the site showing the near infrared fluorescence signal due to diffusion does not increase, whereas ICG-MAA does not increase.
- the complex was found to increase in size over time with the near infrared fluorescence signal.
- ICG-MAA-fibrin complex or ICG-MAA complex was injected subcutaneously in nude mice, and from each complex at the time of injection and 2 days after the injection, The diffusion level of the appearing near infrared fluorescence signal was measured using Xenogen Lumina equipment (FIG. 9).
- Figure 9 is a fluorescence picture showing the diffusion level over time of the ICG-MAA-fibrin complex and ICG-MAA complex injected in nude mice.
- ICG-MAA-fibrin complex is the size of the site showing the near-infrared fluorescence signal due to diffusion even after time due to the aggregation after ICG-MAA is trapped in the fibrin injection
- ICG-MAA complex was found to increase the size of the site showing the near infrared fluorescence signal over time.
- FIG. 10 is a graph showing the labeling rate of the complex conjugated with Tc-99m in MAA. As shown in Figure 10, it was confirmed that the labeling rate is more than 99%.
- ICG near infrared fluorescence signal was measured using Safire II fluorescence equipment (RFU 7,612).
- the complex of the present invention was compared with conventional cancer lesion markers to determine whether the complex of the present invention could be utilized as a cancer lesion marker.
- FIG. 11 is a photograph showing the change in fluorescence signal of each marker over time in mice treated with [Tc-99m] Tc-ICG-MAA and [Tc-99m] Tc-ICG-HSA.
- gelatin sponges showed stability in the body rather than gelatin.
- Example 1 Using the MAA prepared in Example 1, the gold foil coil bonded to the radioisotope prepared in Example 5-1, the gelatin sponge and ICG prepared in Example 5-2 to prepare a solid marker, The characteristics of the near-infrared fluorescence signal resulting therefrom were verified.
- the MAA prepared in Example 1 was mixed with an ICG of 6.5, 65 or 650 ⁇ M, and the mixture was obtained by adding the radioisotope-bound gold foil coil prepared in Example 5-1 to the mixture to obtain a mixture.
- Gelatin was added to the mixture and heated at 160 ° C. for 3 hours, thereby preparing solid markers (Radiogoldcoil / EB-ICG-MAA-Gelatin sponge) including radioactive isotope bound gold foil coil, ICG, MAA and gelatin sponge. .
- FIG. 13 is a photograph showing the change in intensity of the near-infrared fluorescence signal over time of the radioactive isotope-bound gold foil coil, ICG, MAA and gelatin sponge and control group ICG-Spongostan. As shown in FIG.
- the solid-type marker showed a relatively high level of near-infrared fluorescence signal compared to the control group, and after 8 and 24 hours, ICG was diffused in the control group, and distilled water itself. The near infrared fluorescence signal was detected at, whereas the ICG diffusion rate at the solid marker was low.
- the solid markers containing 650 ⁇ M of ICG showed the highest level of near infrared fluorescence signal intensity.
- Example 5-3-2 Comparison of Intensity and ICG Diffusion Levels of Near-Infrared Fluorescence Signals over Time in Mice
- FIG. 14 is a photograph showing the intensity of the near infrared fluorescence signal over time of the solid markers, ICG-Spongostan and ICG-gelatin injected into nude mice. As shown in FIG.
- the near-infrared fluorescence signal was detected in the solid-type marker of the present invention even after three weeks, whereas the near-infrared fluorescence signal was hardly detected in the three-week-old ICG-Spongostan and ICG-gelatin.
- the solid marker of the present invention was injected, it was found that the near-infrared fluorescent signal detected when the ICG concentration used in the preparation of the solid marker was high.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biodiversity & Conservation Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
ICG(μM) | MAA(mg/㎖) | |||
0 | 0.23 | 2.3 | 11.5 | |
1.3 | 18 | 42 | 238 | 530 |
3.9 | 120 | 52 | 424 | 931 |
6.5 | 212 | 38 | 456 | 979 |
9.0 | 289 | 32 | 444 | 942 |
12.9 | 363 | 27 | 342 | 915 |
25.8 | 466 | 12 | 255 | 563 |
38.7 | 425 | 8 | 162 | 366 |
51.6 | 399 | 7 | 101 | 280 |
64.5 | 374 | 13 | 75 | 244 |
77.4 | 332 | 16 | 55 | 182 |
103 | 289 | 23 | 39 | 94 |
258 | 139 | 30 | 16 | 60 |
516 | 71 | 13 | 2 | 20 |
774 | 39 | 6 | 2 | 9 |
1032 | 30 | 6 | 1 | 4 |
Claims (17)
- 대응집알부민(macroaggregated albumin, MAA)에 생체조직 염색용 색소, 방사성 동위원소 또는 이들의 조합이 결합된 복합체를 포함하는 암 병변 표지용 조성물.
- 제1항에 있어서,상기 생체조직 염색용 색소는 육안으로 확인가능한 색소 또는 형광색소인 것을 특징으로 하는 조성물.
- 제2항에 있어서,상기 육안으로 확인가능한 색소는 중성적, 나일청, 비스마르크브라운, 리튬카민, 트리판블루, 야누스그린, 메틸 바이올렛, 오-라민, 마라가이트 그린, 사프라닌, 에오신, 콩고레드, 에리스로신, 니그로신, 알시안블루 헤마톡실린, 아닐린블루, 라이트그린 및 이들의 조합으로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제2항에 있어서,상기 형광색소는 근적외선 형광색소인 것을 특징으로 하는 조성물.
- 제4항에 있어서,상기 근적외선 형광색소는 인도시아닌그린(indocyanine green, ICG)인 것을 특징으로 하는 조성물.
- 제1항에 있어서,상기 방사선 동위원소는 H-3, C-14, P-32, S-35, Cl-36, Cr-51, Co-57, Co-58, Cu-64, Fe-59, Y-90, I-124, I-125, Re-186, I-131, Tc-99m, Mo-99, P-32, CR-51, Ca-45, Ca-68 및 이들의 조합으로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제1항에 있어서,대응집알부민에 피브린이 추가로 결합된 것을 특징으로 하는 조성물.
- 제1항에 있어서,상기 복합체가 젤라틴 또는 젤라틴 스폰지의 내부에 포집된 형태로 존재하는 것을 특징으로 하는 조성물.
- 제8항에 있어서,상기 젤라틴 스폰지는 젤라틴에 존재하는 라이신의 측쇄사슬 아민기와, 글루타메이트 또는 아스파테이트의 측쇄사슬 카복실기 사이에 이소펩티드 결합이 생성된 형태의 구조물인 것을 특징으로 하는 조성물.
- 제1항에 있어서,상기 암은 고형암인 것을 특징으로 하는 조성물.
- 제10항에 있어서,상기 고형암은 전립선암, 유방암, 자궁암, 피부암, 자궁경부암, 폐암, 뇌종양, 위장관 종양, 간암, 연조직육종, 림프종 및 이들의 조합으로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제1항에 있어서,상기 조성물은 암 제거수술중에 실시간으로 암 병변조직의 크기 및 위치를 확인하는데 사용되는 것을 특징으로 하는 조성물.
- 대응집알부민에 (a) 생체조직 염색용 색소, 방사성 동위원소 또는 이들의 조합 및 (b) 피브린이 결합된 복합체를 포함하는 암 병변 표지용 조성물로서, 상기 복합체는 젤라틴 스폰지의 내부에 포집된 조성물.
- (a) 제1항 내지 제13항 중 어느 한 항의 조성물을 개체에서 발생된 암의 병변에 투여하는 단계; 및,(b) 상기 개체로부터 색깔, 근적외선 형광, 방사선 및 이들의 조합으로 구성된 군으로부터 선택되는 신호를 확인하는 단계를 포함하는, 암 병변의 위치에 대한 정보를 제공하는 방법.
- 제1항 내지 제13항 중 어느 한 항의 조성물을 포함하는 암 병변 표지용 키트.
- 제15항에 있어서,상기 키트는 암 제거수술 중에 실시간으로 암 병변조직의 크기 및 위치를 확인하는데 사용되는 것을 특징으로 하는 키트.
- 대응집알부민에 생체조직 염색용 색소가 결합된 복합체.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13866879.3A EP2940474B1 (en) | 2012-12-26 | 2013-12-04 | Novel labeling composition for cancer lesion |
CN201380068248.5A CN104919319B (zh) | 2012-12-26 | 2013-12-04 | 新型癌症病变标记用组合物 |
JP2015550299A JP6174713B2 (ja) | 2012-12-26 | 2013-12-04 | 新規な癌病変標識用組成物 |
CA2896464A CA2896464C (en) | 2012-12-26 | 2013-12-04 | Novel labeling composition for cancer lesion |
ES13866879T ES2725352T3 (es) | 2012-12-26 | 2013-12-04 | Nueva composición de etiquetado de lesión cancerosa |
RU2015131003A RU2619556C2 (ru) | 2012-12-26 | 2013-12-04 | Новая метящая композиция для ракового поражения |
US14/758,179 US10166302B2 (en) | 2012-12-26 | 2013-12-04 | Labeling composition for cancer lesion |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0153793 | 2012-12-26 | ||
KR1020120153793A KR101552138B1 (ko) | 2012-12-26 | 2012-12-26 | 신규한 암 병변 표지용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014104605A1 true WO2014104605A1 (ko) | 2014-07-03 |
Family
ID=51021600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/011177 WO2014104605A1 (ko) | 2012-12-26 | 2013-12-04 | 신규한 암 병변 표지용 조성물 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10166302B2 (ko) |
EP (1) | EP2940474B1 (ko) |
JP (1) | JP6174713B2 (ko) |
KR (1) | KR101552138B1 (ko) |
CN (1) | CN104919319B (ko) |
CA (1) | CA2896464C (ko) |
ES (1) | ES2725352T3 (ko) |
RU (1) | RU2619556C2 (ko) |
WO (1) | WO2014104605A1 (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170099737A (ko) * | 2016-02-23 | 2017-09-01 | 노을 주식회사 | 접촉식 염색 패치 및 이를 이용하는 염색 방법 |
KR102478639B1 (ko) * | 2016-02-23 | 2022-12-19 | 노을 주식회사 | 표지 물질을 저장하는 패치, 이를 이용하는 조직 진단 방법 및 장치 |
US10371610B2 (en) | 2016-02-23 | 2019-08-06 | Noul Co., Ltd. | Contact-type patch, staining method using the same, and manufacturing method thereof |
WO2017183946A1 (ko) * | 2016-04-22 | 2017-10-26 | 국립암센터 | 병변 표지용 주사제 조성물 |
KR102179241B1 (ko) | 2016-04-22 | 2020-11-16 | 국립암센터 | 병변 표지용 주사제 조성물 |
CN107865971A (zh) * | 2016-09-26 | 2018-04-03 | 清弘生医股份有限公司 | 组织定位组成物 |
CN107181976B (zh) * | 2017-04-28 | 2021-01-29 | 华为技术有限公司 | 一种弹幕显示方法及电子设备 |
JP7312822B2 (ja) * | 2018-11-06 | 2023-07-21 | ナショナル キャンサー センター | 注入型ヒドロゲルシステムおよび病変の標識方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4094965A (en) * | 1977-04-01 | 1978-06-13 | New England Nuclear Corporation | Diagnostic agents containing albumin and method for making same |
WO1998043680A1 (en) * | 1997-03-31 | 1998-10-08 | Order Stanley E | Method for treating solid tumors comprising injecting macroaggregated albumin to increase retention time or radioactive/therapeutic agent in tumors |
WO2000074727A2 (en) * | 1999-06-04 | 2000-12-14 | Resolution Pharmaceuticals, Inc. | Radiopharmaceuticals and methods for imaging |
KR20110009271A (ko) | 2006-12-22 | 2011-01-27 | 퀄컴 인코포레이티드 | 디코더측 관심 영역 비디오 프로세싱 |
KR20110135833A (ko) * | 2010-06-11 | 2011-12-19 | 국립암센터 | 종양 및 감시림프절에 특이적인 방사성동위원소 표지된 엽산 결합 인혈청 알부민 |
KR20120015849A (ko) * | 2010-08-13 | 2012-02-22 | 국립암센터 | 방사성 동위원소가 표지되고 근적외선 영역의 형광색소 및 가시광선 영역의 색소가 결합된 알부민을 포함하는 감시림프절 표지자 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845202A (en) * | 1972-10-24 | 1974-10-29 | Administrator Of Veterans Affa | Lung scanning protein macroaggregate of indium 113m in a sulfide-sulfur composition |
IL142864A0 (en) * | 1998-11-12 | 2002-03-10 | Novolytics Inc | Compositions and methods for producing vascular occlusion |
CA2459794C (en) * | 2001-09-12 | 2012-08-21 | Virexx Medical Corp. | Vascular occlusion solid-phase agent with immobilised platelet binding agent |
WO2009116556A1 (ja) | 2008-03-19 | 2009-09-24 | 富士フイルム株式会社 | 注射用医薬組成物 |
CN101773677B (zh) * | 2010-03-02 | 2011-08-24 | 中国人民解放军南京军区南京总医院 | 一种活体肿瘤显像靶分子及其特异性探针 |
EP2471557A1 (en) | 2010-12-27 | 2012-07-04 | Università degli Studi di Genova | A conjugate of human albumin and 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid useful for the localization of radionuclides for diagnostic and therapeutic purposes |
-
2012
- 2012-12-26 KR KR1020120153793A patent/KR101552138B1/ko active IP Right Grant
-
2013
- 2013-12-04 US US14/758,179 patent/US10166302B2/en active Active
- 2013-12-04 CN CN201380068248.5A patent/CN104919319B/zh active Active
- 2013-12-04 EP EP13866879.3A patent/EP2940474B1/en active Active
- 2013-12-04 CA CA2896464A patent/CA2896464C/en active Active
- 2013-12-04 WO PCT/KR2013/011177 patent/WO2014104605A1/ko active Application Filing
- 2013-12-04 ES ES13866879T patent/ES2725352T3/es active Active
- 2013-12-04 RU RU2015131003A patent/RU2619556C2/ru active
- 2013-12-04 JP JP2015550299A patent/JP6174713B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4094965A (en) * | 1977-04-01 | 1978-06-13 | New England Nuclear Corporation | Diagnostic agents containing albumin and method for making same |
WO1998043680A1 (en) * | 1997-03-31 | 1998-10-08 | Order Stanley E | Method for treating solid tumors comprising injecting macroaggregated albumin to increase retention time or radioactive/therapeutic agent in tumors |
WO2000074727A2 (en) * | 1999-06-04 | 2000-12-14 | Resolution Pharmaceuticals, Inc. | Radiopharmaceuticals and methods for imaging |
KR20110009271A (ko) | 2006-12-22 | 2011-01-27 | 퀄컴 인코포레이티드 | 디코더측 관심 영역 비디오 프로세싱 |
KR20110135833A (ko) * | 2010-06-11 | 2011-12-19 | 국립암센터 | 종양 및 감시림프절에 특이적인 방사성동위원소 표지된 엽산 결합 인혈청 알부민 |
KR20120015849A (ko) * | 2010-08-13 | 2012-02-22 | 국립암센터 | 방사성 동위원소가 표지되고 근적외선 영역의 형광색소 및 가시광선 영역의 색소가 결합된 알부민을 포함하는 감시림프절 표지자 |
Non-Patent Citations (1)
Title |
---|
T. KITAI ET AL., BREAST CANCER, vol. 12, 2005, pages 211 - 215 |
Also Published As
Publication number | Publication date |
---|---|
CN104919319B (zh) | 2017-12-08 |
CA2896464C (en) | 2018-10-23 |
EP2940474B1 (en) | 2019-02-13 |
RU2015131003A (ru) | 2017-01-30 |
US20150328345A1 (en) | 2015-11-19 |
KR20140083727A (ko) | 2014-07-04 |
US10166302B2 (en) | 2019-01-01 |
EP2940474A1 (en) | 2015-11-04 |
RU2619556C2 (ru) | 2017-05-16 |
KR101552138B1 (ko) | 2015-09-10 |
JP6174713B2 (ja) | 2017-08-02 |
CN104919319A (zh) | 2015-09-16 |
JP2016511745A (ja) | 2016-04-21 |
ES2725352T3 (es) | 2019-09-23 |
CA2896464A1 (en) | 2014-07-03 |
EP2940474A4 (en) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014104605A1 (ko) | 신규한 암 병변 표지용 조성물 | |
Van Den Berg et al. | Hybrid tracers for sentinel node biopsy | |
van der Poel et al. | Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer | |
Tummers et al. | Intraoperative guidance in parathyroid surgery using near-infrared fluorescence imaging and low-dose Methylene Blue | |
Brouwer et al. | Feasibility of sentinel node biopsy in head and neck melanoma using a hybrid radioactive and fluorescent tracer | |
KR101228147B1 (ko) | 방사성 동위원소가 표지되고 근적외선 영역의 형광색소 및 가시광선 영역의 색소가 결합된 알부민을 포함하는 감시림프절 표지자 | |
Peng et al. | Sentinel node biopsy using indocyanine green in oral/oropharyngeal cancer | |
Ross et al. | The ability of lymphoscintigraphy to direct sentinel node biopsy in the clinically N0 neck for patients with head and neck squamous cell carcinoma | |
Park et al. | Mapping of the perigastric lymphatic network using indocyanine green fluorescence imaging and tissue marking dye in clinically advanced gastric cancer | |
Gambini et al. | Hybrid tracers and devices for intraoperative imaging: the future for radioguided surgery? | |
Kairemo | Immunolymphoscintigraphy with 99mTc-labeled monoclonal antibody (BW 431/26) reacting with carcinoembryonic antigen in breast cancer | |
Soo et al. | Radioimmunoscintigraphy of squamous carcinomas of the head and neck | |
KR20150042170A (ko) | 신규한 수술용 표지제 조성물 | |
Das et al. | Real-time fluorescence imaging in thoracic surgery | |
KR102179241B1 (ko) | 병변 표지용 주사제 조성물 | |
Rychlik et al. | Tracers and corresponding detection devices: technetium colloids, blue dyes & NIR fluorescence | |
van den Berg MSc et al. | (Near-infrared) fluorescence-guided surgery under ambient light conditions: a next step to embedment of the technology in clinical routine | |
WO2017183946A1 (ko) | 병변 표지용 주사제 조성물 | |
WO2023136639A1 (ko) | 생체 친화적 목적 병변 표지용 조성물 및 이의 제조 방법 | |
Han et al. | Development of a multi-modal imaging system for single-gamma and fluorescence fusion images | |
JP6748789B2 (ja) | 色素カップリングマンノシル血清アルブミン複合体およびこれを含むリンパ節プロービング組成物 | |
Mukhopadhyay et al. | 64Cu-Bevacizumab as a better PET imaging agent in detecting breast cancer in MDA-MB-231 orthotopic and bone metastasis mice model compared to 18FDG | |
TWI424853B (zh) | 以放射性標誌之anti-GRP78 peptide偵測大腸癌方法 | |
Kondov et al. | Identification of Sentinel Lymph Node in Breast Cancer with three Tracers (Radiocolloid, Methylene blue, and Indocyanine Green).(Case Report). Open Access Maced J Med Sci. 2020 Sep 10; 8 (C): 94-98 | |
PARK et al. | Dual tracer imaging for localization of parathyroid lesions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13866879 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013866879 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015550299 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2896464 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14758179 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015131003 Country of ref document: RU Kind code of ref document: A |